Furthermore, although the role of TRM in tumour immunology is still not well understood, intra-tumoural T cells expressing the integrin CD103, which is indicative of TRM, have been reported to correlate with a favourable prognosis in cancer patients (reviewed by Dumauthioz et al. [166]), and TRM have been shown to have anti-tumour activity in preclinical models [167, 168]. The gene discussed is ITGAE; the disease is neoplasm.